Differencial proteome of clear-cell renal cell carcinoma(ccRCC) tissues

International Braz J Urol

Volumn 39, Issue 1, 2013, Pages 83-94

  de Ribeiro, Ana Júlia Vieira ^a   Sandim, Vanessa ^a   Ornellas, Antonio Augusto ^a,b   Reis, Rodrigo Siqueira ^c   Domont, Gilberto ^c   Alves, Gilda ^a  

^a National Cancer Institute   (Brazil)

^b Hospital Mário Kroeff   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Carcinoma; Electrophoresis; Kidney; Polyacrylamide Gel; Proteome; Renal Cell

Indexed keywords

PROTEOME; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CHEMISTRY; FEMALE; HUMAN; KIDNEY; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MASS SPECTROMETRY; MIDDLE AGED; PATHOLOGY; TWO DIMENSIONAL GEL ELECTROPHORESIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84878452781     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-5538.IBJU.2013.01.11     Document Type: Article

References (32)

1. Campbell SC, Novick AC. Renal Tumors. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ (Editors), Kavoussi LR, Novick AC, Partin AW, Peters CA (ed.), Campbell's Urology, Philadelphia, Elsevier, 2002; pp. 2672-86.
2. Ries LA, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al.: (ed.), SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http:// seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER website, 2008.
3. Sarto C, Marocchi A, Sanchez JC, Giannone D, Frutiger S, Golaz O, et al.: Renal cell carcinoma and normal kidney protein expression. Electrophoresis. 1997; 18: 599-604.
4. Hwa JS, Park HJ, Jung JH, Kam SC, Park HC, Kim CW, et al.: Identification of proteins differentially expressed in the conventional renal cell carcinoma by proteomic analysis. J Korean Med Sci. 2005; 20: 450-5.
5. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, et al.: Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer. 2006; 5: 64.
6. Jones J, Otu HH, Grall F, Spentzos D, Can H, Aivado M, et al.: Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer. J Urol. 2008; 179: 730-6.
7. Siu KW, DeSouza LV, Scorilas A, Romaschin AD, Honey RJ, Stewart R, et al.: Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J Proteome Res. 2009; 8: 3797-807.
8. Raimondo F, Salemi C, Chinello C, Fumagalli D, Morosi L, Rocco F, et al.: Proteomic analysis in clear cell renal cell carcinoma: identification of differentially expressed protein by 2-D DIGE. Mol Biosyst. 2012; 8: 1040-51.
9. Engwegen JY, Mehra N, Haanen JB, Bonfrer JM, Schellens JH, Voest EE, et al.: Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Invest. 2007; 87: 161-72.
10. Görg A, Weiss W, Dunn MJ: Current two-dimensional electrophoresis technology for proteomics. Proteomics. 2004; 4: 3665-85. Erratum in: Proteomics. 2005; 5: 826-7.
11. Balabanov S, Zimmermann U, Protzel C, Scharf C, Klebingat KJ, Walther R: Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis. Eur J Biochem. 2001; 268: 5977-80.
12. Pierce A, Mirzaei H, Muller F, De Waal E, Taylor AB, Leonard S, et al.: GAPDH is conformationally and functionally altered in association with oxidative stress in mouse models of amyotrophic lateral sclerosis. J Mol Biol. 2008; 382: 1195-210.
13. Mazzola JL, Sirover MA: Alteration of intracellular structure and function of glyceraldehyde-3-phosphate dehydrogenase: a common phenotype of neurodegenerative disorders?. Neurotoxicology. 2002; 23: 603-9.
14. Immenschuh S, Baumgart-Vogt E: Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal. 2005; 7: 768-77.
15. Nonn L, Berggren M, Powis G: Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res. 2003; 1: 682-9.
16. Soini Y, Kallio JP, Hirvikoski P, Helin H, Kellokumpu-Lehtinen P, Kang SW, et al.: Oxidative/nitrosative stress and peroxiredoxin 2 are associated with grade and prognosis of human renal carcinoma. APMIS. 2006; 114: 329-37.
17. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P: Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol. 2004; 53: 209-19.
18. Soprano DR, Soprano KJ, Goodman DS: Retinol-binding protein messenger RNA levels in the liver and in extrahepatic tissues of the rat. J Lipid Res. 1986; 27: 166-71.
19. Park KS, Kim H, Kim NG, Cho SY, Choi KH, Seong JK, et al.: Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma. Hepatology. 2002; 35: 1459-66.
20. McClung JK, Danner DB, Stewart DA, Smith JR, Schneider EL, Lumpkin CK, et al.: Isolation of a cDNA that hybrid selects antiproliferative mRNA from rat liver. Biochem Biophys Res Commun. 1989; 164: 1316-22.
21. Nuell MJ, Stewart DA, Walker L, Friedman V, Wood CM, Owens GA, et al.: Prohibitin, an evolutionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells. Mol Cell Biol. 1991; 11: 1372-81.
22. Wang S, Nath N, Adlam M, Chellappan S: Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Wang S, Nath N, Adlam M, Chellappan S. Oncogene. 1999; 18: 3501-10.
23. Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S: Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem. 2003; 278: 47853-61.
24. Junker H, Venz S, Zimmermann U, Thiele A, Scharf C, Walther R: Stage-related alterations in renal cell carcinoma- -comprehensive quantitative analysis by 2D-DIGE and protein network analysis. PLoS One. 2011; 6: e21867.
25. Kathiria AS, Butcher LD, Feagins LA, Souza RF, Boland CR, Theiss AL: Prohibitin 1 modulates mitochondrial stressrelated autophagy in human colonic epithelial cells. PLoS One. 2012; 7: e31231.
26. Takashi M, Sakata T, Ohmura M, Kato K: Elevated concentrations of the small stress protein HSP27 in rat renal tumors. Urol Res. 1997; 25: 173-7.
27. Shi T, Dong F, Liou LS, Duan ZH, Novick AC, DiDonato JÁ: Differential protein profiling in renal-cell carcinoma. Mol Carcinog. 2004; 40: 47-61.
28. Holcakova J, Hernychova L, Bouchal P, Brozkova K, Zaloudik J, Valik D, et al.: Identification of alphaB-crystallin, a biomarker of renal cell carcinoma by SELDI-TOF MS. Int J Biol Markers. 2008; 23: 48-53.
29. Santarosa M, Favaro D, Quaia M, Galligioni E: Expression of heat shock protein 72 in renal cell carcinoma: possible role and prognostic implications in cancer patients. Eur J Cancer. 1997; 33: 873-7.
30. Erkizan O, Kirkali G, Yörükoglu K, Kirkali Z: Significance of heat shock protein-27 expression in patients with renal cell carcinoma. Urology. 2004; 64: 474-8.
31. Sarto C, Valsecchi C, Magni F, Tremolada L, Arizzi C, Cordani N, et al.: Expression of heat shock protein 27 in human renal cell carcinoma. Proteomics. 2004: 2252-60.
32. Kim DS, Choi YP, Kang S, Gao MQ, Kim B, Park HR, et al.: Panel of candidate biomarkers for renal cell carcinoma. J Proteome Res. 2010; 9: 3710-9.